South African pharmaceutical company Aspen Pharmacare is currently in advanced negotiations with key partners to start the production of mpox vaccines at its facilities. This was revealed by Chief Executive Officer Stephen Saad in an interview with Reuters on Tuesday.
“We are speaking to people, we have the capabilities, we can do it,” Saad stated confidently, suggesting that Aspen Pharmacare is well-prepared to take on the vaccine manufacturing process.
The move underscores the company’s ongoing efforts to expand its role in the global pharmaceutical landscape, particularly in the realm of vaccine production.
(With inputs from agencies.)
This article was originally published by a www.devdiscourse.com . Read the Original article here. .